OMY Stock Overview
Synairgen plc discovers and develops drugs for respiratory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Synairgen plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.05 |
| 52 Week High | UK£0.083 |
| 52 Week Low | UK£0.038 |
| Beta | -2.4 |
| 11 Month Change | 0% |
| 3 Month Change | -15.68% |
| 1 Year Change | n/a |
| 33 Year Change | -97.38% |
| 5 Year Change | -47.92% |
| Change since IPO | -77.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| OMY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.8% |
| 1Y | n/a | -16.9% | 9.1% |
Return vs Industry: Insufficient data to determine how OMY performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how OMY performed against the German Market.
Price Volatility
| OMY volatility | |
|---|---|
| OMY Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OMY has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OMY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 36 | Richard Marsden | www.synairgen.com |
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Synairgen plc Fundamentals Summary
| OMY fundamental statistics | |
|---|---|
| Market cap | €9.98m |
| Earnings (TTM) | -€9.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.0x
P/E RatioIs OMY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMY income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£8.41m |
| Earnings | -UK£8.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.042 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OMY perform over the long term?
See historical performance and comparison